Home › Stocks › Pharma & healthcare stocks › Laurus Labs
Pharma & healthcare stocks Valuation research

Laurus Labs valuation — from HIV drugs to contract manufacturing

Laurus Labs made its name in ingredients for HIV medicines. Its growth now depends on contract manufacturing for global drug companies.

FairStocks Research
Updated 15 Nov 2026 · 4 min read
| NSE: LAURUSLABS ₹2,424
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
Laurus Labs (LAURUSLABS) valuation — what today's price assumes? Price ₹2,424, P/E 97.7, P/B 24.71, ROE —. Based on 10 years of reported financials. FairStocks.
Laurus Labs at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 15 Nov 2026.
In 30 seconds

We do not publish one number for Laurus Labs — and here is why.

On today's figures the market pays roughly 3.9 times what our model says Laurus Labs is worth. On a company this widely followed, a gap that large almost always means our model is missing something rather than that thousands of investors are wrong. So we show the workings and say plainly that we cannot stand behind a single figure here.

  • How it is valued: no single figure is published here — our model and the market disagree too far.
  • What the price assumes: 35% growth, against 11% the model takes from its own record.
  • Ten-year record: Between FY2018 and FY2026, Laurus Labs' revenue went from ₹2,069 crore to ₹6,813 crore — it compounded at about 16% a year over 8 years.
  • Biggest swing factor: CDMO contracts. Main risk: Customer concentration.
Price
₹2,424
Market cap
₹1.31L Cr
P/E
97.7
P/B
24.71
See the full Laurus Labs workingsEvery step of the Laurus Labs working, the scenarios and the report Free during launch →

01A Hyderabad API and CDMO company

Laurus Labs, founded in Hyderabad in 2005 by Dr Satyanarayana Chava, is a major maker of active pharmaceutical ingredients for antiretroviral (HIV) and other medicines, and of finished generic drugs.

Its contract development and manufacturing (CDMO) business makes ingredients for global pharmaceutical companies' patented drugs, and it is investing in biotech and cell and gene therapy capacity.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Laurus Labs, next to what the model assumes from the company's own record.

Market expects
35%
growth priced into today's price
Model assumes
11%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Laurus Labs' record, in plain numbers

Between FY2018 and FY2026, Laurus Labs' revenue went from ₹2,069 crore to ₹6,813 crore — it compounded at about 16% a year over 8 years. Net profit grew from ₹168 crore to ₹890 crore, about 23% a year — faster than revenue, so margins widened. In FY2026 it kept 13.1% of revenue as net profit — against a low of 3.2% in FY2024 and a high of 20.4% in FY2021. The latest year added 22.7% to revenue, well ahead of its own long-run pace.

Reading the record. The FY2021 profit peak came from pandemic-era demand; the FY2024 dip followed falling prices for HIV ingredients and one-off contract work ending.
Revenue₹0.02L → ₹0.07L Cr
181920212223242526
Earnings per share₹15.8 → ₹16.5
181920212223242526
Return on equity40.4% → 18.6%
23242526
Debt to equity0.19 → 0.12
23242526

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY20182,0691688.1%
FY20192,292944.1%
FY20202,8322559.0%
FY20214,81498420.4%
FY20224,93683216.9%
FY20236,04179313.1%
FY20245,0411623.2%
FY20255,5543586.5%
FY20266,81389013.1%

04How Laurus Labs gets valued — and why

Estimate withheld — model and market disagree too far

Our model and the market disagree so far apart on this company that the model is the more likely one to be wrong. Rather than publish a number we cannot stand behind, we show the workings and say so.

05What decides Laurus Labs' value

CDMO contracts

Long-term work for innovators drives margins.

ARV pricing

HIV ingredient prices have fallen.

New capacity

Investment must be filled with orders.

Biotech

New platforms are long-term options.

06What could go wrong

  • Customer concentration. A few large contracts matter a lot.
  • Price erosion. Generic ingredient prices keep falling.
  • The premium. The price assumes CDMO growth delivers.

07What the full Laurus Labs valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Laurus Labs valuation

  • ✓The full model workings — and exactly where the model and the market part ways
  • ✓Every assumption — growth, returns and cost of capital, with sources
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Divi's Laboratories, Aurobindo Pharma and other drugmakers
  • ✓Downloadable report — the full write-up, yours to keep
See the full Laurus Labs workings — free
Free during launch · unlimited valuations · no card required

08Questions people ask about Laurus Labs

What does Laurus Labs make?

Ingredients and finished drugs for HIV and other diseases, plus contract manufacturing.

What is a CDMO?

A contract development and manufacturing organisation that makes drug ingredients for other companies.

Why did Laurus Labs' profit fall in FY2024?

Lower ARV prices and the end of some one-off contract work.

Is Laurus Labs overvalued?

At ₹2,424 the market is pricing in roughly 35% sustained growth, against the ~11% its own record supports. That is more than it has delivered, so the price is justified only if the business can hold a rate it has not previously sustained.

What is the intrinsic value of Laurus Labs?

This business is a group of operations with different economics, so a single blended figure would describe none of them. The parts are valued separately and the breakdown is in the report, rather than one number that cannot be defended.

How much debt does Laurus Labs carry?

Debt to equity stands at 0.12, down from 0.19 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from Laurus Labs' filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See the full Laurus Labs workingsUnlock free